Literature DB >> 7564729

Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D.

J C Wu1, K B Choo, C M Chen, T Z Chen, T I Huo, S D Lee.   

Abstract

The outcome of hepatitis D virus (HDV) superinfection varies among patients and in different geographical areas. To find out whether HDV genotype affects outcome, we used a simple genotyping method based on restriction-fragment length polymorphism with enzymes XhoI and SacII for cleavage of PCR products of the HDV genome. Of samples from 88 patients studied, the genotypes of 61 were confirmed by two methods--analysis with both enzymes or by combined restriction-enzyme and direct sequencing analyses--with consistent results. No genotype III HDV was detected among these patients. The majority of patients with acute HDV infection (35/41 [85%]) had genotype II HDV. Among the 41 patients with acute infection, four of six with genotype I had fulminant disease compared with two of 35 with genotype II. Among patients in chronic stage, cirrhosis or hepatocellular carcinoma were found in 12 of 18 with genotype I HDV and eight of 29 with genotype II. Thus genotype II was the predominant HDV genotype in this study in Taiwan. Genotype II HDV was less frequently associated with fulminant hepatitis at the acute stage or with an unfavourable long-term clinical outcome at the chronic stage than was genotype I.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7564729     DOI: 10.1016/s0140-6736(95)91558-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  32 in total

1.  Molecular phylogenetic analysis of Iranian HDV complete genome.

Authors:  Farida Behzadian; Farzaneh Sabahi; Mohsen Karimi; Majid Sadeghizadeh; Nader Maghsoudi; Ramin Sarrami Forooshani; Leila Shahinsaz
Journal:  Virus Genes       Date:  2005-05       Impact factor: 2.332

2.  Current prevalence of hepatitis delta virus (HDV) infection and the range of HDV genotypes in Lebanon.

Authors:  S Ramia; M El-Zaatari; A I Sharara; F Ramlawi; B Farhat
Journal:  Epidemiol Infect       Date:  2006-12-19       Impact factor: 2.451

3.  Clathrin-mediated post-Golgi membrane trafficking in the morphogenesis of hepatitis delta virus.

Authors:  Cheng Huang; Shin C Chang; Hui-Chin Yang; Chung-Liang Chien; Ming-Fu Chang
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

Review 4.  Life cycle and pathogenesis of hepatitis D virus: A review.

Authors:  Zaigham Abbas; Rafia Afzal
Journal:  World J Hepatol       Date:  2013-12-27

Review 5.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

6.  Phylogenetic analysis of hepatitis D viruses indicating a new genotype I subgroup among African isolates.

Authors:  Y Y Zhang; E Tsega; B G Hansson
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

Review 7.  Hepatitis D virus coinfection and superinfection.

Authors:  Francesco Negro
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

Review 8.  Hepatitis D and hepatocellular carcinoma.

Authors:  Zaigham Abbas; Minaam Abbas; Sarim Abbas; Lubna Shazi
Journal:  World J Hepatol       Date:  2015-04-18

Review 9.  The evolution and clinical impact of hepatitis B virus genome diversity.

Authors:  Peter A Revill; Thomas Tu; Hans J Netter; Lilly K W Yuen; Stephen A Locarnini; Margaret Littlejohn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-05-28       Impact factor: 46.802

10.  Hepatitis D virus genotypes in intravenous drug users in taiwan: decreasing prevalence and lack of correlation with hepatitis B virus genotypes.

Authors:  Jia-Horng Kao; Pei-Jer Chen; Ming-Yang Lai; Ding-Shinn Chen
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.